Sofinnova Partners has followed up the succession of IPOs by its portfolio companies with the sale of its stake in GlycoVaxyn to GlaxoSmithKline. The sale continues a busy two years for the VC shop.
France's Inotrem is working up a novel approach to the global scourge of sepsis, and now, thanks to some high-profile investors, the biotech has $25 million to take its immunotherapy from the benchtop to the clinic.
The British biotech has rounded up $28 million (£17.5 million) in first-round venture cash from a group of marquee investors willing to bet big that Crescendo's mouse platform can deliver the best in cutting-edge antibody fragment therapeutics.
Swiss biotech Auris Medical has raised $50.6 million in a series C round of financing to advance its two major therapeutics for the treatment of inner ear disorders.
Bucking weak investor interest in the life sciences, Paris-based Sofinnova--a longtime player in biotech venture circles--has put together a $312 million fund that will be entirely dedicated to the life sciences.
The U.K's wealthiest charity has blueprinted big plans to back fledgling therapeutics and diagnostics companies with a brand new £200 million ($317 million) fund.
Europe may becoming a major draw for venture capital, Xconomy reports.